Company Valuation: NFL Biosciences

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025
Market Cap 1 12.56 10.29 11.67 19.12 14.93
Change - -18.12% 13.49% 63.78% -21.92%
Enterprise Value (EV) 1 9.443 9.155 9.206 17.05 13.31
Change - -3.05% 0.56% 85.17% -21.93%
P/E -12.8x -4.21x -3.14x -9.56x -4.62x
PBR 3.82x 12.2x 33.6x 19.8x 48.8x
PEG - -0x 1.88x 0.2x -0.2x
Capitalization / Revenue 322,130x 467,546x 58.4x 415,647x 79,404x
EV / Revenue 242,134x 416,129x 46x 370,592x 70,790x
EV / EBITDA -11x -3.02x -2.21x -6.26x -3.51x
EV / EBIT -10.5x -2.97x -2.18x -6.11x -3.44x
EV / FCF - - - - -
FCF Yield - - - - -
Dividend per Share 2 - - - - -
Rate of return - - - - -
EPS 2 -0.1869 -0.4668 -0.459 -0.206 -0.255
Distribution rate - - - - -
Net sales 1 0.000039 0.000022 0.2 0.000046 0.000188
EBITDA 1 -0.8584 -3.031 -4.174 -2.723 -3.786
EBIT 1 -0.9019 -3.083 -4.23 -2.79 -3.873
Net income 1 -0.9782 -2.443 -3.745 -2.081 -3.318
Net Debt 1 -3.12 -1.131 -2.467 -2.073 -1.619
Reference price 2 2.4000 1.9650 1.4400 1.9700 1.1780
Nbr of stocks (in thousands) 5,235 5,235 8,107 9,705 12,672
Announcement Date 29/4/22 28/4/23 14/4/25 14/4/25 27/4/26
1EUR in Million2EUR
Estimates

P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
- - - - 12.48M
34.42x8.62x26.79x0.05% 56.21B
20.89x6.41x13.9x1.44% 55.38B
-18.72x4.62x-8.06x-.--% 23.75B
-40.52x13.41x-39.1x-.--% 23.19B
22.61x4.44x11.53x-.--% 18.14B
23.61x4.69x15.54x-.--% 16.84B
47.98x19.44x60.62x-.--% 15.86B
16.99x4.92x11.55x-.--% 13.56B
-455.4x31.15x-3472.99x-.--% 12.97B
Average -38.68x 10.86x -375.58x 0.17% 23.59B
Weighted average by Cap. -10.17x 9.32x -179.19x 0.35%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. ALNFL Stock
  4. Valuation NFL Biosciences